RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA
Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat leukemia: triple-drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) in 72 adults with acute myeloid leukemia that has returned or not responded to prior therapy. The goal is to see if this combo can achieve complete remission. Participants will recei…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated May 17, 2026 03:43 UTC
-
New hope for hard-to-treat leukemia: experimental drug lisaftoclax enters human testing
Disease control Recruiting nowThis study tests a new drug called lisaftoclax (APG-2575) in people with acute myeloid leukemia (AML) that has returned or not improved with standard treatments. The drug is given alone or together with other medicines (homoharringtonine or azacitidine). The main goals are to che…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 04, 2026 16:20 UTC